|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000017260 |
|
Date of registration:
|
24/04/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
A study of the effect of long-term anticholinergic administration -solifenacin succinate-
|
|
Scientific title:
|
A study of the effect of long-term anticholinergic administration -solifenacin succinate- - A study of the effect of long-term anticholinergic administration |
|
Date of first enrolment:
|
2008/12/07 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020002 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Hiroshi Tanaka |
|
Address:
|
North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan
Japan |
|
Telephone:
|
011-706-5966 |
|
Email:
|
h-tanaka@med.hokudai.ac.jp |
|
Affiliation:
|
Hokkaido University Graduate School of Medicine Department of Renal and Genitourinary surgery |
|
|
Name:
|
Hiroshi Tanaka |
|
Address:
|
North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan
Japan |
|
Telephone:
|
011-706-5966 |
|
Email:
|
h-tanaka@med.hokudai.ac.jp |
|
Affiliation:
|
Hokkaido University Graduate School of Medicine Department of Renal and Genitourinary surgery |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1)Patients who has contraindication of solifenacin succinate 2)Patients with prostate cancer 3)Patients with dutrusor underactivity 4)Patients with history of urethral stricture 5)Patients with history of radiation therapy 6,7)Patients with bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis. 8)Patients with using self catheterization 9)Patients with history of resistance to anti-holinergic agents 10)Any other patients who are regarded as unsuitable for this study by the investigator
Age minimum:
20years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
overactive bladder
|
|
Intervention(s)
|
|
Solifenacin succinate 5 mg will be orally administered once a day after breakfast for 52 weeks.
|
|
Primary Outcome(s)
|
|
We explore the factors that affect their usefulness in agent.
|
|
Source(s) of Monetary Support
|
|
none
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|